Bristol-Myers Squibb Company was founded in 1887 by a pair of young entrepreneurs, William McLaren Bristol and John Ripley Myers, in Mr. Bristol’s hometown of Clinton, New York. “I have often wondered at our nerve,” Mr. Bristol would later recall, thinking back to the enterprise’s early days. He and Mr. Myers invested $5,000, a princely sum at the time, into a near-bankrupt business neither man knew anything about: ethical pharmaceuticals.

Bristol-Myers Squibb has grown rapidly over the years, with its greatest growth coming from the merger with the Squibb Corporation in 1989, the largest single stock transfer in the history of the health care industry. Squibb had been founded by Dr. Edward Robinson Squibb in 1858.

Today, more than 100 years after the company's founding, the pioneering spirit of Mr. Bristol and Mr. Myers transformed that risky $5,000 investment into a $12 billion, diversified global health and personal care company with more than 47,000 employees worldwide and thousands of products marketed in more than 130 countries.

Bristol-Myers Squibb Worldwide Pharmaceuticals is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous systems and dermatologic disorders, and cancer. Established in 1938, the Bristol-Myers Squibb Pharmaceutical Research Institute is a global research and development organization dedicated to translating frontier scientific knowledge into new, commercially viable pharmaceutical therapies. Therapeutic areas of research include oncology, cardiovascular and metabolics, anti-infectives, neurosciences, immunology and inflammation, dermatology, and pain management.

Bioanalytical Systems, Inc.